Physician
Mountain View Pain Specialists
Mountain View Pain Specialists was paid $9.91M by Medicaid between Aug 2018 and Dec 2024, across 36 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 29% of everything it billed.
33Billing provider infoMOUNTAIN VIEW PAIN SPECIALISTS
LONE TREE, CO 80124
LONE TREE, CO 80124
33aNPI1912403544assigned 04/03/2018
33bProvider typeInterventional Pain Medicine Physician
28Total paid$9.91M
24GClaims160,779
24DCodes billed36
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Colorado
Rank by total paid#1 of 8
Median peer was paid$192K
This provider vs. median52×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 120 | $9K | |
| 2019 | 2,492 | $144K | |
| 2020 | 6,944 | $435K | |
| 2021 | 20,762 | $1.35M | |
| 2022 | 30,334 | $1.90M | |
| 2023 | 49,435 | $2.80M | |
| 2024incomplete | 50,692 | $3.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 42,125 | 33,516 | $2.91M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 29,112 | 23,550 | $1.36M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 9.5% | 9,469 | 8,086 | $939K |
| 64483 | 8.4% | 6,672 | 4,134 | $837K | |
| 64484 | 5.4% | 5,544 | 3,408 | $535K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 5.4% | 4,105 | 3,301 | $535K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 4.2% | 2,819 | 2,132 | $420K |
| 64635 | 3.8% | 1,523 | 971 | $379K | |
| 77002 | 3.0% | 5,212 | 3,386 | $296K | |
| 64493 | 2.4% | 3,449 | 1,484 | $234K | |
| 62321 | 2.1% | 2,767 | 2,449 | $213K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.9% | 271 | 207 | $193K |
24 more codes
| 20610 | 1.5% | 4,038 | $151K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 4,449 | $151K |
| 20553 | 1.3% | 3,468 | $127K | |
| 64494 | 1.1% | 3,332 | $113K | |
| 64636 | <1% | 1,399 | $69K | |
| 64633 | <1% | 246 | $68K | |
| 27096 | <1% | 810 | $67K | |
| 64490 | <1% | 830 | $64K | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 3,897 | $57K |
| 80306 | <1% | 2,535 | $34K | |
| 64634 | <1% | 239 | $31K | |
| 64491 | <1% | 808 | $30K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 8,343 | $24K |
| 64615 | <1% | 247 | $18K | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 248 | $17K |
| 64495 | <1% | 350 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,850 | $9K |
| 20552 | <1% | 248 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 506 | $7K |
| 64492 | <1% | 76 | $3K | |
| 64450 | <1% | 89 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 90 | $623.93 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 516 | $607.17 |
| J3490 | Unclassified drugs | 0% | 97 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGABRIEL, SHAUN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Mountain View Surgical Specialists | Denver, CO | $126K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.